Adding local therapy after osimertinib plus chemo for EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer with an EGFR mutation (exon 19 deletion or L858R).
- You have completed four cycles of osimertinib plus platinum-based chemo as your first treatment.
- Your cancer has shrunk or stayed stable after those cycles.
- The main tumor in your lung can still be treated with surgery or radiation.
- You are age 20 or older, and your daily activity level is good (ECOG 0 or 1).
- You do not have untreated or unstable brain metastases, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial tests whether adding precise, high-dose radiation (SBRT) to the targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has shrunk but not disappeared on osimertinib alone.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests a combination of two drugs, osimertinib and etoposide, for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding well to osimertinib alone. It may help if your cancer is stable or slowly getting worse on osimertinib as your first treatment.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.